Podcasts about Jazz Pharmaceuticals

Get ready to Talk About It! Or in Greg's case, answer about it! In this two-part series, Greg takes on your 20 most-asked questions and responds from the heart, giving authentic insight from an epilepsy advocate and caregiver. In this part 1, we cover some of the heavy questions that weigh on patients and caregivers, from "why me?" to "what can I do about caregiver burnout?" Social isolation, disagreements among parent caregivers, driving safety, refusal to take meds - these are all things that patients and caregivers have to confront head-on, and Greg is here to provide a steady voice in the conversation for you. We always say on this show, "everybody has something" and remind you that epilepsy doesn't define your life. But that doesn't mean that these questions aren't coming from real emotions and frustrations, or that it is wrong to ask altogether. The first step in finding answers, or at least dealing with the emotions behind the questions, is to talk to other people about it. Greg might not have all the answers, but he certainly speaks from his heart. Give this episode a listen and let us know if you agree or disagree - even disagreements lead to talking about it! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

We here at Talk About It are so excited about our expansion into helping raise awareness for conditions that are related to epilepsy. One of the conditions at the top of our list is autism spectrum disorder. Did you know that approximately 25-30% of children with ASD will develop epilepsy in their lifetime? But not only are these conditions medically correlated, they also share similarities when it comes to bullying, stigma, job prospects, dating, and everyday life experience. That means, of course, we need to TALK ABOUT IT! Greg sits down in studio with his good friend Holly Robinson Peete, an actress who has lit up our screen since her breakout role in 21 Jump Street in 1987 and has gone on to star in so many of our favorite movies and shows. Together with her husband, former NFL quarterback and Heisman trophy candidate Rodney Peete, they started the HollyRod Foundation to help families battling a Parkinson's diagnosis, but expanded into autism after their eldest son RJ, a twin, was diagnosed with autism spectrum disorder. The foundation helps to provide medical, financial, and emotional support for families affected by these conditions.  With the guidance and support of his amazing parents, RJ has defied the odds to overcome all of the "nevers" - never saying he loves them, never getting a quality education, never being able to socialize, never being able to hold a job - a stigma that still plagues families dealing with this disorder, and increasingly being mainstreamed by people in power. RJ now is a clubhouse attendant for the Los Angeles Dodgers, and an integral part of their team's family dynamic. Holly and Greg discuss his role on the team, the bullying that their family went through, dating on the spectrum, and the importance of job placement for those with spectrum disorders. This is such a heartwarming episode and you will learn so much! Don't miss it! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Sit... Stay... Talk about it! This incredible episode is all about our very best friends, and the most adorable heroes of the epilepsy community, dogs! Greg chats with Katie Gonzalez, founder of Little Angels Service Dogs. LASD is a nonprofit that trains incredible canine candidates and passes the graduates on to families in need of a service dog for so many medical conditions, from seizure alert to autism help, mobility assistance, diabetes, stress and anxiety disorders, and so many more.  In this part 1 (part 2 is coming soon where Greg will go to the center and see the training in action), they talk about the dogs' incredible ability to detect an oncoming seizure by smelling chemical changes in a person's body. Katie has not only dedicated her life to training these incredible animals, but also to the science behind these chemical changes and how dogs can detect it. She even wrote the book - literally - on training your service dog based on this research!  Plus, Greg asks general questions about best practices when it comes to our good boys and good girls, and Greg and Nick battle over who has the cuter dog. Do not miss this episode, otherwise you won't get your treat! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest innovations, strategic shifts, and regulatory updates shaping the industry.Johnson & Johnson's Tecvayli, a promising monotherapy for multiple myeloma, has shown remarkable efficacy in clinical trials. By reducing the risk of disease progression or death by 71% among patients resistant to anti-CD38 therapies, Tecvayli is setting a new standard in oncological treatment. This breakthrough underscores not only its potential as a standalone therapy but also highlights significant advancements in managing multiple myeloma—a cancer notoriously difficult to treat and manage.In regulatory developments, Sanofi has recently completed pricing negotiations with U.S. policymakers, gaining much-needed clarity on drug pricing regulations. However, Sanofi remains cautious as evolving policies could impact future operations. This scenario is emblematic of the broader industry challenge: navigating an uncertain regulatory landscape while maintaining stability and profitability in volatile markets.Astellas Pharma is adapting to its looming patent cliff for the prostate cancer drug Xtandi by focusing on innovation as a strategy for sustainable growth. With patent protection set to expire next year, Astellas emphasizes innovation over acquisitions for revenue protection, reflecting a broader industry trend towards long-term growth strategies rather than short-term gains.Meanwhile, Jazz Pharmaceuticals has sold a priority review voucher for $200 million, highlighting the persistent value of these vouchers which expedite FDA review processes. Such vouchers are becoming essential strategic assets as companies seek competitive advantages through faster market entry.On the technological front, Becton Dickinson's $110 million investment to expand syringe production capabilities demonstrates efforts to meet rising demand for injectable medications like GLP-1s. This initiative not only addresses immediate supply chain needs but also aligns with broader discussions about reshoring pharmaceutical manufacturing in the U.S., enhancing domestic production capabilities.Financially, strategic trends were a focal point at the recent J.P. Morgan Healthcare Conference. Although large-scale mergers and acquisitions were anticipated, none materialized, suggesting an evolving focus towards strategic partnerships and incremental innovations over mega-mergers among industry stakeholders.Looking ahead, AbbVie's projection of strong growth into the 2030s is driven by a robust pipeline and strategic initiatives. As companies navigate a complex landscape defined by innovation demands and regulatory changes, such outlooks underscore the industry's commitment to sustaining growth and innovation while improving patient outcomes through novel treatments and technologies.Italian pharmaceutical company Alfasigma's acquisition of rights to an injectable treatment for HSV encephalitis from a German biotech firm further exemplifies strategic investments aimed at expanding therapeutic portfolios with innovative solutions addressing critical health needs. This move is significant given the limited therapeutic options available for this severe condition.The Novo Nordisk Foundation's $860 million investment in Denmark's BioInnovation Institute underscores efforts to strengthen local biotech ecosystems. By nurturing homegrown biotech and deep tech companies, this initiative positions Denmark as a prominent hub for research and development while facilitating the translation of scientific discoveries into viable therapeutic solutions.Ocugen's promising mid-phase data for its gene therapy targeting eye disease positions it as a potential competitor against market leaders like Apellis and Astellas. The positive phase 2 results highlight gene therapy's growiSupport the show

Happy New Year from all of us at Talk About It! In this special to kick off the new year, Greg and Nick take a look back at some of the best moments that sparked conversation in 2025 and reflect on what could be learned from them. It was incredibly difficult to narrow down our top moments, since every guest brings such engaging and valuable conversations when talking about their epilepsy journey or their insight into various aspects of being a caregiver or living with epilepsy, but we did our best! As you watch or listen, be sure to go back and watch the full episode on talkaboutit.org, because we really are only skimming the surface of hours of incredible conversation. You did such a great job last year - keep up the great work with journaling, taking medication, getting good sleep and sustaining a good diet and exercise routine, and as always... keep TALKING ABOUT IT! These are some of the moments that we break down in this year-in-review: Epilepsy for Dummies - Elizabeth A. Thiele, MD, PhD, and Lauren Seeley Aguirre distill the entire world of epilepsy - from diagnosis, to treatment, to stigma and the challenges that arise - into one comprehensive book. This episode was incredibly popular, so we naturally had to cover it first! Tony Coelho shares his story of passing the ADA - Former House Representative Tony Coelho goes through his story of incredible persistence as he navigated the difficult hurdles of Congress and administrative pushback to get President George H.W. Bush to sign the ADA into law. He then kept up his spirits to keep battling after the Supreme Court rolled back much of what he fought for, and successfully got President George W. Bush to amend the legislation with a new bill in his favor. As a bonus, we also see Tony Coelho tell his story of standing up for what he believed is right... to the POPE! Sunflower Syndrome - Cal volleyball player Peyton DeJardin and Young Adults With Epilepsy member Abigayle Weitl each shared a story of their epilepsy journey in different episodes with incredibly similar details. Both were misdiagnosed as having a tick disorder when they were young due to an unconscious behavior of waving their fingers in front of their eyes when looking at the sun to trigger a seizure, and then both developed Jeavons syndrome as adults. We often say on this show that you'll never find a mirror, but if you search for your community, they are out there - no matter how rare your condition.  Conversations with your Care Team - Dr. Janet Greenwood and Dr. Barry Gidal each joined the podcast this year to answer questions for experts, and they both had great insight into the importance of being open and honest with your healthcare team and the importance of them being open and honest back. Self advocacy is so important, so be sure to keep a journal and write down questions ahead of time so that you make your doctor visits more efficient, and then take notes while in that meeting! Additionally, Dr. Gidal talks about the importance of checking your prescription before leaving the pharmacy to make sure it looks the same. Social Influencing - We see Jaime Simpson and Stanzi Potenza each talking about their social media profiles, and sharing the importance of using your platform to raise awareness about epilepsy. Let this be an inspiration for you to use whatever tools you have - it doesn't have to be social media - to advocate for others and share your story. Communities are so important in the world of epilepsy, so build yours with the thing you love to do! Alan Faneca - In Nick's personal favorite episode, former Pittsburgh Steeler and NFL Hall of Fame Inductee Alan Faneca joined the show to talk about his epilepsy journey, and being the dad of a daughter with epilepsy, as well. Speaking of using platforms for advocacy, Alan even included his epilepsy diagnosis in his Hall of Fame Induction speech to inspire others not to give up in the face of adversity.  And finally, we hear from Dr. Barry Gidal once more to hear about the positive future for epilepsy research.  Be inspired! Use your voice! Go into this year Talking About It and building our community! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA information, and to apply for credit, please visit us at PeerView.com/PYJ865. CME/AAPA credit will be available until January 5, 2027.Innovation Takes the Lead in SCLC: Leveraging Evolving Advances to Drive Improved Outcomes in Limited- and Extensive-Stage Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent medical education grants from Amgen; Genentech, a member of the Roche Group; and Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Kenneth Galbraith, CEO and Board Chair at Zymeworks, a biotech developing multispecific therapies internally and through partnerships with companies including Jazz Pharmaceuticals and BeOne Medicines (formerly BeiGene), J&J, Merck, Daiichi Sankyo, and GSK. Ken talks about Zymeworks' shift to a royalty model for development funding and value creation, lessons learned from platform deals and cross-border R&D, the benefits of strong royalty agreements and backloaded milestone payments over headline upfronts, and industry dynamics for the coming year. Ken also shares insights from his deep experiences as a biotech investor and corporate director, and explains why scientific primacy should always drive biotech business decisions.         Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements and strategic movements shaping the future of healthcare.The pharmaceutical and biotech sectors are undergoing significant transformations, driven by scientific breakthroughs, regulatory developments, and strategic shifts. At the forefront is Eli Lilly's impressive lineup of investigational cardiometabolic drugs, spotlighted in Clarivate's "Drugs to Watch in 2026" report. This signals a robust focus on combating cardiometabolic disorders, which have vast implications for global health due to their widespread prevalence. The report also highlights Johnson & Johnson's competitive position in this therapeutic area, indicating a dynamic landscape where innovation is key.In oncology, Jazz Pharmaceuticals is making waves with its bispecific antibody, Ziihera, positioning it as a preferred HER2-targeted therapy for stomach cancer. This development marks a shift towards precision medicine and targeted therapies, which are gradually supplanting traditional treatments like Herceptin. The promising efficacy of Ziihera could revolutionize treatment protocols for HER2-positive gastric cancer patients, enhancing survival outcomes and quality of life.Meanwhile, a legal confrontation has erupted between Bayer and leading COVID-19 vaccine developers such as Moderna, Johnson & Johnson, and Pfizer-BioNTech. Bayer alleges patent infringement on intellectual property developed years prior. This lawsuit underscores the intricate relationship between innovation and intellectual property rights in the pharmaceutical industry, especially poignant in the aftermath of the COVID-19 pandemic.Daiichi Sankyo's collaboration with Genesis to commercialize Vanflyta—an acute myeloid leukemia treatment—across 13 European countries highlights strategic movements in oncology. Approved in 2023, this partnership exemplifies Daiichi's commitment to expanding its European market presence and improving patient access to critical cancer therapies.GSK's promising Phase 3 results for its hepatitis B drug candidate represent a potential breakthrough as a "functional cure." Such advancements could redefine management strategies for hepatitis B, a chronic infection affecting millions worldwide. The positive trial outcomes pave the way for FDA submission, showcasing GSK's dedication to addressing unmet medical needs through innovative approaches.Amgen's strategic partnership with Disco Pharmaceuticals illustrates ongoing investment in oncology research. With a $618 million agreement focused on cancer target discovery, Amgen leverages Disco's expertise to fortify its oncology pipeline. This collaboration underscores the significance of cooperative innovation in drug development and enhancing therapeutic options.In gene therapy, Ikarovec and VectorBuilder are advancing eye disease treatments through an innovative partnership. Their $1 billion deal aims to make gene therapies more accessible by enabling administration outside specialized settings—a transformative approach that could democratize advanced treatments.Hope Biosciences' Phase 2 study results offer hope for Parkinson's disease patients through stem cell therapy improvements in motor function. Despite some data discrepancies, these findings set the stage for Phase 3 trials and underscore the potential of stem cell therapies in neurological disorders.The pharmaceutical industry also grapples with economic challenges as layoffs rise by 16% year-over-year in 2025. Concurrently, despite regulatory hurdles and macroeconomic uncertainties, the FDA approved 55 new treatments and vaccines—a testament to resilience and innovation within biopharma.In regulatory dynamics, GSK's Exdensur received approval in Japan for treating severe asthma and chronic rhinosinusitisSupport the show

Happy Holidays and Happy New Year from your Talk About It family! We are closing an incredible year with a great episode that features people leading the charge from the next generation. The young adults who are receiving the torch to advocate for epilepsy awareness into the future! Greg chats with Abigayle Weitl and Chels Scantland from the Young Adults with Epilepsy organization that aims to provide young adults with resources to gain independence and break stigmas through education, awareness, mental health counseling, and so many incredible programs that they offer. They discuss each of their journeys with epilepsy and how they got involved in the organization, and how they have used their own experiences to impact the lives of the next generations. They also discuss tips for new years celebrations if you have epilepsy, strategies for preserving mental health in a social media world, and the importance of belonging when diagnosed with a condition like epilepsy. Greg then gives thanks for an incredible year we have had and sets his sights on the big things happening next year at Talk About It. We need your help! Like and share this episode, follow Talk About It on YouTube, and get involved in great organizations like Young Adults with Epilepsy! Have a safe and happy holiday season, and we will see you in the new year! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

In this episode, Dr John Heymach and Dr Solange Peters discuss key data presented at the IASLC World Conference on Lung Cancer including first-line maintenance in ES-SCLC (IMforte and DeLLphi-303 trials) and targeted treatment for NSCLC (FLAURA2, Beamion LUNG-1, and ARROS-1 trials).Presenters:John Heymach, MD, PhDChair and ProfessorDepartment of Thoracic/Head and Neck Medical OncologyRuth Legett Jones Distinguished ChairMD Anderson Cancer CenterHouston, TexasSolange Peters, MD, PhD Professor and Director of Medical OncologyDepartment of OncologyUniversity Hospital of LausanneLausanne, SwitzerlandContent based on an online CME program supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Jazz Pharmaceuticals, Inc.Link to full program: https://bit.ly/3L1eksIGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome back to the Oncology Brothers podcast! In this episode, we continue the CME series on HER2-positive GEJ and gastric cancer, shifting focus to the essential topic of treatment toxicity management. We're joined by two leading experts: Dr. Geoffrey Ku from Memorial Sloan Kettering and Dr. Shruti Patel from Stanford University. Building on their previous discussion of upper GI treatment algorithm with Dr. Rutika Mehta, this episode delves into the practical realities of managing patients on complex regimens. Drs. Ku & Patel break down the side effect profiles across the treatment continuum—from frontline trastuzumab-based combinations to emerging therapies like zanidatamab—and provide actionable strategies for community oncologists. Episode Highlights: • Practical management of frontline side effects with FOLFOX/XELOX chemotherapy plus trastuzumab and pembrolizumab • Reality check on trastuzumab cardiotoxicity: incidence rates and monitoring protocols in gastric vs. breast cancer • Immune-related adverse events with checkpoint inhibitors: what's common vs. rare in GI cancers • Critical insights on zanidatamab's synergistic diarrhea toxicity and mandatory prophylaxis strategies • TDXd (Enhertu) in second-line: moving beyond ILD fears to address frequent cytopenias and marrow management • Expert consensus on infusion reaction management for novel biologics • The importance of managing baseline symptoms in patients with dysphagia and nausea This episode bridges the gap between trial data and clinical practice, offering real-world wisdom on keeping patients on effective therapies through proactive toxicity management. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for our complete CME series covering treatment algorithms, FDA approvals, and practical management strategies! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/navigating-the-adverse-event-landscape-in-her2-gea-therapy

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Rutika Mehta, a GI medical oncologist from Weill Cornell. Together, we dived into the current treatment landscape for advanced metastatic gastroesophageal junction (GEJ) and gastrointestinal carcinoma, with a special focus on HER2-positive disease. Episode Highlights: • Overview of recent advancements in the treatment of resectable disease, including the approval of Durvalumab in perioperative settings. • Discussion on the importance of biomarker testing, including HER2, PD-L1, MMR, and Claudin 18.2, in determining treatment options. • Insights into frontline treatment strategies for HER2-positive patients, including the role of trastuzumab and the addition of pembrolizumab based on PD-L1 status. • The significance of retesting HER2 expression upon disease progression and the implications for treatment decisions. • Exploration of emerging therapies like TDXd and Zanidatamab, and their potential impact on the treatment landscape. • Considerations for managing side effects and the importance of treatment sequencing in palliative care. Join us for an informative discussion that aims to keep community oncologists up to date in this ever-evolving field of cancer treatment. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to subscribe for more episodes covering treatment algorithms, FDA approvals, and conference highlights! Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/biomarker-testing-in-her2-gea-diagnosis-and-treatment-implications    #HER2GastricCancer #GastricCancer #BiomarkerTesting #OncologyBrothers #GIOncology #CME

Take a seat on the couch. Take some space. Tell us what's on your mind. This episode is all about therapy! Greg is relatively new to the world of therapy, and there is no guest more fitting to have on this week's episode than his personal therapist Brian Wry! Brian is a licensed marriage and family therapist with his own practice, and he has some great insight into the importance of therapy for anybody, including those affected by epilepsy - whether you are a patient or a caregiver. They discuss how to find a therapist and the patience that it may require, finding a reset for your mind, the nature of human interaction having a positive impact on physiology and the risks of people using resources like Chat GPT as therapy in order to save money. Plus, Greg walks us through the process of creating his "Ticket Bowls" and the value that they have beyond looking really cool! Do not miss this episode, it is so important for you to get your mind right! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

This episode, Heather and Seth record at the NCLifeSci 2025 Annual Meeting with Tom Croce, Vice President of Global Patient Advocacy and Engagement at Jazz Pharmaceuticals. Tom shares how his team integrates patient perspectives across the entire drug development and commercialization process, and why “patient centricity” is transforming the pharmaceutical industry. We explore the growing role of patient input in clinical trials, the future of advocacy-driven innovation, and more. Tune in for an insightful discussion on building better treatments by listening to the people who need them most.

From all of us at Talk About It!, HAPPY THANKSGIVING! This week, we are SERVING up a very special episode that will make you want seconds - an incredible story to watch or listen to while you prep your holiday dinner! Greg chats with Peyton DeJardin, a senior at University of California Berkeley and a force on the volleyball court. When she was just a young girl, she developed a self-induced photosensitive epilepsy or "sunflower syndrome" which later turned into Jeavons syndrome which would sometimes cause upwards of 100 small seizures per day. It took years to correctly diagnose her condition as epilepsy, but despite her diagnosis, she has never let it get in her way. Her competitive spirit and positive attitude make her a volleyball star at Cal, and her awareness and resolve help her to inform others about her condition and point out ways in which environments might trigger her or others to have seizures so that changes can be made. They discuss how lighting can be a trigger for photosensitive epilepsy and how she spreads awareness about that in class or on the court, and her epilepsy journey through being a young kid into her adulthood. Greg also revisits a previous interview about Helmets 4 Helmets because of their UC Berkeley connection, and gives many thanks for Thanksgiving along with tips on how to talk about epilepsy at the dinner table this holiday. Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a host of transformative events reshaping the landscape, from strategic acquisitions and funding infusions to regulatory maneuvers and scientific breakthroughs.Johnson & Johnson has taken a decisive step in its oncology strategy with the $3 billion acquisition of Halda's cell death technology. This acquisition, focusing on the "hold and kill" bifunctional small molecule platform, is poised to enhance J&J's prostate cancer pipeline significantly. It underscores J&J's commitment to expanding its oncology portfolio through innovative platforms designed to improve therapeutic outcomes. The move highlights a broader industry trend toward personalized medicine and targeted cancer therapies, which are becoming pivotal in improving patient care.In another domain of cancer treatment, Nuvalent has unveiled promising Phase 1/2 data for its candidate neladalkib, which could position the company as a formidable competitor to Pfizer's established lung cancer drug, Lorbrena. The promising data might expedite regulatory discussions with the FDA, potentially leading to an accelerated approval process. This development illustrates the competitive landscape in oncology, where firms strive to introduce novel therapies with improved efficacy and safety profiles.The field of antibody-drug conjugates (ADCs) is also experiencing significant advancements. A San Diego-based biotech has secured $120 million in funding to develop a best-in-class ADC formula, with support from Merck & Co. This initiative aims to refine the precision and efficacy of ADCs by delivering cytotoxic agents directly to cancer cells while minimizing collateral damage to healthy tissues. Such innovations are crucial as they represent a new frontier in targeted cancer therapy.In terms of financial activities, Artios Pharma's successful $115 million Series D funding round is set to bolster its clinical efforts in exploring DNA damage response inhibitors for cancer treatment. These inhibitors target cancer cells' ability to repair DNA damage, holding potential for more effective therapies against resistant cancer types. Meanwhile, Sofinnova Partners' €650 million raise for biotech and medtech investments amid a volatile economic environment underscores continued investor confidence in life sciences despite market uncertainties.Bayer is making strategic moves in China by opening an incubator in Beijing. This facility will host local biopharma companies such as Suzhou Puhe Biopharma and Beijing Youngen Technology, fostering innovation and collaboration within China's burgeoning biotech landscape. Such initiatives reflect global efforts to leverage regional strengths and foster cross-border collaborations.On the operational side, Nxera Pharma is restructuring its workforce by laying off 15% of its staff as part of a strategic pivot towards profitability. This decision mirrors broader industry trends where companies refocus resources on core projects to streamline operations and enhance financial stability.A recent study has highlighted the impact of NIH grant cuts on clinical trials across the United States. Over 383 trials involving more than 74,000 patients have been disrupted due to funding terminations under the current administration. This situation raises concerns about the sustainability of clinical research funding and its implications for ongoing medical advancements.Jazz Pharmaceuticals has reported practice-changing Phase 3 results for its HER2-targeted drug Ziihera for gastroesophageal adenocarcinoma. These findings reaffirm Jazz's confidence in positioning Ziihera as a preferred first-line treatment option for HER2-positive cancers, poSupport the show

Happy Epilepsy Awareness Month from Talk About It! As the title says, this month is all about making people aware of epilepsy and what to do if you see someone having a seizure. Remember... STAY - Remain with the person until they are awake and alert. SAFE - Keep the person safe and move them away from harm. SIDE - Turn the person on their side and put something soft under their head. For this very special episode, we are talking about something that is SO IMPORTANT but is rarely shared with new parents, febrile seizures. Greg brings on his good friend Trevor Gretzky to share their terrifying story about his daughter having a febrile seizure, and having no idea what was happening or why. How is it possible that young parents aren't prepared for this given how common it is, and how can we all get the message out about febrile seizures? It starts with, you guessed it, talking about it! Do not miss this episode, this is SO important. Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Boo! Welcome to the first Halloween Special from Talk About It! This episode is all treats and no tricks. Greg sits down with his good friend who has his fair share of people dressing as his characters for trick-or-treating or Halloween festivities - actor Jeff Daniel Phillips! Jeff has done everything from being the Geico caveman on all of our screens to Herman Munster in Rob Zombie's remake of the classic spooky family, and he joins the podcast to talk about a new project that he wrote, directed and starred in called Cursed in Baja. The movie centers around his character that takes a trip to Mexico in search of his fortune, but has seizure-like episodes that take him into another scary world. They talk about portraying seizures on screen and the best ways to go about those scenes, and the positive and negative examples of that being done. Also, they talk about Halloween, Jeff's work with Rob Zombie, tips for celebrating Halloween when you have epilepsy or are a caregiver to someone with epilepsy, and of COURSE.... the Geico Caveman. This episode is so much fun, you don't want to miss it! Have a safe and happy Halloween, everybody! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Welcome to part two of embracing our dummy-ness! In this episode, Greg continues the conversation with Dr. Elizabeth Thiele, a neurologist and epileptologist, and Lauren Aguirre, an author, journalist, epilepsy patient and caregiver to her children that also have epilepsy. They authored the next installment of the incredibly popular "For Dummies" series of books from Wiley, and their book "Epilepsy for Dummies" will be everywhere books are sold at the end of the month, but you can pre-order or download it in digital formats NOW! In this part two, they discuss looking at epilepsy from the perspective of both the patient and the medical professional which really helped them take a wholistic look at the condition for the book, the ketogenic diet, all of the valuable information that can be found within the book, new research in TSC, and stick around for the end because they take rapid fire questions from Greg about epilepsy and caregiving. There is so much valuable information in this episode, which is just a taste of what you will find within the pages of their new book. Seriously, folks, whether you are a patient with epilepsy, a caregiver, an educator, or just a good citizen, you NEED to get your copy!  Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EPE865. CME credit will be available until September 16, 2026.Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EPE865. CME credit will be available until September 16, 2026.Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EPE865. CME credit will be available until September 16, 2026.Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EPE865. CME credit will be available until September 16, 2026.Mastering Cannabinoid Science: Key Insights for Informed Clinical Decision-Making In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent medical education grant from Jazz Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

Do you feel like a dummy sometimes? Are you someone living with epilepsy, caregiving for someone with epilepsy, or want to know what to do in case you have to administer aid to someone having a seizure? Are you a teacher, coach, family member or friend of somebody who has epilepsy and you feel uninformed about epilepsy and wish there was a comprehensive guide for... well.. dummies? FINALLY, the book that everybody needs has arrived! From Wiley, the makers of the "For Dummies" series of books, comes a new installment:  Epilepsy for Dummies! Your complete guide to understanding all aspects of the epilepsy journey. Greg sits down with the authors of this book - Dr. Elizabeth Thiel, a neurologist and epileptologist, and Lauren Aguirre, an author, journalist, epilepsy patient and caregiver to her children that also have epilepsy - for a very special TWO PART series that dives into the book and the process of writing it. In part one, they discuss the inspiration for writing it, the rapidly-expanding knowledge of epilepsy and potential genetic causes of seizures, wearable technology and the future of epilepsy treatment, qualities of a doctor that patients value, and so much more! There is so much expertise between these two authors, you NEED this book and this podcast! Pre-order Epilepsy for Dummies now, or own it immediately in digital format! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Nick is STILL in control and Grunny isn't liking it! On this episode of Talk About It, we conclude this short two-part series in which Nick asks Greg questions that have come in over time from caregivers, people living with epilepsy, and even questions that Nick has for Greg. If you missed part one, we encourage you to go back and hear Greg speak candidly about his family's experience on the journey with Jake and reminding you that you are not alone and there is support for you. This episode gets more practical - discussing Jake's routines that he has established to minimize the potential for a seizure, how to talk to medical professionals when you have appointments, how to research treatements, and what is in store for the future of Talk About It! Get your notebooks out and be ready for all the invaluable information that you are about to hear! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.  

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Two-time Emmy and Three-time NAACP Image Award-winning, television Executive Producer Rushion McDonald interviewed Dr. Isaiah Tatum. A 24-year-old entrepreneur, touring artist, and hotel owner:

Today we sit down with Henry Ford Health Michigan's Hina Desai, an oncology certified social worker with decades of experience, to share her best caregiving tips for those supporting transplant patients. Hina explains that patience, physical stamina, problem-solving, adaptability, and emotional intelligence are essential caregiver skills. We talk about the many roles a caregiver plays — from transportation and medication management to wound care, infection prevention, meal preparation, and emotional support. Staying connected to the healthcare team and keeping friends and family informed are key.We highlight the value of resources like the Leukemia & Lymphoma Society's, now Blood Cancer United's, free nutritional consultations. Hina stresses the importance of understanding the Family Medical Leave Act, planning for potential income loss, and connecting with social workers to access financial help from foundations such as LLS, PAN Foundation, Cancer Care, Angels of Hope, New Day Family Foundation, and NMDP.Hina advises enlisting a support network early. Dividing tasks like grocery shopping, meal prep, transportation, and pharmacy runs helps prevent burnout. She reminds us that transplant caregiving is a marathon — caregivers must look after their physical, emotional, financial, and spiritual wellbeing. This includes setting boundaries, filtering advice, staying flexible, and preparing for setbacks such as relapse or unexpected hospital stays.We discuss unique considerations for CAR T, allogeneic, and autologous transplants. CAR T caregivers should watch for neurological changes. Allogeneic caregivers may handle tasks like IV magnesium infusions and monitor for graft-versus-host disease (GVHD) or veno-occlusive disease (VOD).Caregiving can change relationship dynamics, sometimes causing role reversal. Good communication helps maintain mutual respect. Self-care remains vital: nutritious eating, exercise, spiritual practices, adequate sleep, and support groups can all help sustain the caregiver's energy and emotional health.Hina and Peggy share heartwarming stories of caregivers going above and beyond, from offering a shower to a hospital-bound spouse, to creatively negotiating with doctors so a patient could return to gardening safely. We reflect on the importance of kindness toward oneself, seeking help when needed, and recognizing that caregiving doesn't have to be perfect to be deeply meaningful.  We also highlight three husbands who have stepped up as caregivers to their wives.We close with gratitude for caregivers and the countless ways they support recovery, comfort, and hope for transplant patients.Season 18 of the Marrow Masters podcast is sponsored by Sanofi and Jazz Pharmaceuticals.This season is sponsored by Sanofi: https://www.sanofi.com/And Jazz Pharmaceuticals: https://www.jazzpharma.com/Resources:Leukemia & Lymphoma Society (LLS) is now Blood Cancer United: https://bloodcancerunited.org/PAN Foundation: https://www.panfoundation.orgCancer Care: https://www.cancercare.orgAngels of Hope: https://angelsofhope.orgNew Day Foundation for Families: https://www.foundationforfamilies.orgNational Marrow Donor Program (NMDP): https://bethematch.orgBMT InfoNet: https://www.bmtinfonet.org National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Given that Season 18 of Marrow Masters focuses on caregiving, we wanted to share an empathy exercise that the LINK's licensed staff social worker, Jennifer Gillette, performed in a recent webinar. It's impossible to know exactly what a cancer patient is going through, but through this exercise, you may get a bit of understanding. And it may help you garner some empathy for the person you are caring for.This season of Marrow Masters is Sponsored by Sanofi and Jazz Pharmaceuticals. National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome to Season 18 of Marrow Masters, produced for the National Bone Marrow Transplant Link, and sponsored by Sanofi and Jazz Pharmaceuticals. This season is all about the caregivers. Our guests will offer up their best tips, experiences and advice. We'll cover the importance of self-care and share heartwarming stories of compassion and love. You'll hear from an RN and transplant manager at Atlanta's Northside Hospital, a CEO of a cancer organization who found herself in the cargiver role, an oncology social worker, a survivor who had an army of caregivers, and a male and female caregiver. You'll want to hear how those roles affected the dynamics of their relationships.   This season, we're also including an empathy exercise- demonstrated by the National Bone Marrow Transplant LINK's own social worker, Jennifer Gillette. While most of us are fortunate not to know first-hand what it's like to have cancer, this exercise will open your eyes to what your loved one may be experiencing.Please share this podcast with someone you think would benefit from it.  And don't miss future episodes of our show – follow Marrow Masters for free on Apple, Spotify, YouTube, or wherever you're listening right now.  Marrow Masters is produced for the National Bone Marrow Transplant Link. Established in 1992, the LINK strives to help patients, caregivers, and families cope with the psychosocial challenges of bone marrow transplant, from diagnosis through survivorship.  The Marrow Masters podcast is produced by JAG Podcast productions, online at JAGPodcastProductions.com.This season is sponsored by Sanofi: https://www.sanofi.com/And Jazz Pharmaceuticals: https://www.jazzpharma.com/ National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.To participate in the GVHD Mosaic, click here: https://amp.livemosaics.com/gvhd Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Welcome back to the Oncology Brothers podcast! In this episode, we continue the three-part CME series on small cell lung cancer, focusing on adverse events and management strategies for extensive stage small cell lung cancer treatments. We are thrilled to have Dr. Misty Shields from the Indiana University join us to discuss the latest advancements in treatment options following the exciting data presented at ASCO 2025. We dived into the treatment algorithm for patients with good performance status, including the use of chemoimmunotherapy, lurbinectedin, and tarlatamab. Key topics covered in this episode: •⁠  ⁠Overview of the current treatment landscape and new data from ASCO 2025 •⁠  ⁠Common side effects associated with lurbinectedin and immunotherapy •⁠  ⁠Strategies for managing adverse events, including hematologic toxicities and liver function monitoring •⁠  ⁠The role of supportive care and palliative care in enhancing patient quality of life •⁠  ⁠Collaboration between community oncologists and academic centers for optimal patient care Join us as we explore the challenges and opportunities in managing extensive stage small cell lung cancer, and learn how to provide the best care for patients facing this devastating disease. Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/practical-considerations-and-future-directions-for-new-treatment-strategies-in-sclc Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ #SCLCtoxicity #Lurbinectedin #Tarlatamab #SupportiveOncology #CMEoncology

Take cover, everybody, Producer Nick has the reigns! Over the years, Talk About It has received so many questions from viewers ranging from how to deal with an epilepsy diagnosis, to what to do if you are a caregiver, to practical quesitons about establishing routines and how to prevent seizures. Every episode, we are all privileged to hear these incredible conversations from a range of guests and experts, but we have an expert sitting right there, every time: Greg! He has gone through what caregivers go through, he has dealt with medication and emerging treatments, he has become an expert on what to do when his son Jake has a seizure, and so has his family. In this special two-part AMA series of Talk About It, Greg will be in the guest seat answering questions in a real and candid way to provide a peek behind the curtain of his experiences and offer advice from one person in the community to another.  This is part one, and you don't want to miss it!  Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Welcome to the Oncology Brothers podcast! In this episode, we kick off a three-part CME series focused on small cell lung cancer (SCLC). Joined by Dr. Hossein Borghaei, Chief of Thoracic Oncology at the Fox Chase Cancer Center. Together they dived into the evolving treatment landscape for SCLC, highlighting recent advancements and data from ASCO 2025. Episode Highlights: •⁠  ⁠Overview of the current standard of care for limited and extensive-stage SCLC. •⁠  ⁠Discussion on the role of concurrent chemoradiation therapy and the new standard of care involving immunotherapy. •⁠  ⁠Insights into the use of lurbinectedin in maintenance therapy and its impact on overall survival. •⁠  ⁠Exploration of the promising results from the DeLLphi study on tarlatamab, a bispecific antibody, and its implications for treatment. •⁠  ⁠The importance of patient selection and managing side effects in treatment decisions. Join us as we navigate the complexities of SCLC treatment and look forward to future advancements that may improve patient outcomes. Accreditation/Credit Designation Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial Support This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc. Link to gain CME credits from this activity: https://www.gotoper.com/courses/breaking-down-the-latest-clinical-data-for-first-line-maintenance-and-rr-sclc  Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ #OncologyBrothers #SmallCellLungCancer #CME #ASCO2025 #LungCancer #Immunotherapy #CancerTreatment

The Guru Returns! Welcome to the concluding episode of this two-part series with health and fitness trainer/ influencer Dylan Holvey. Dylan has a private practice in the Los Angeles area where he consults with clients about workout regiments and diet, but he has also built an impressive social media following that educates his followers about healthy living. In addition, he has a weekly podcast called The Holvey Hour that is available everywhere you get your podcasts, and you should definitely be listening to every episode. This episode gets deeper into the steps that we can all take to build habits and a lifestyle that makes positive changes. It's not about taking big swings or starting programs that are unsustainable, it's about doing one thing a day to improve your diet or exercise, and then building on that to create habits. As Dylan says, if it feels too daunting to be able to do for 30 years, then don't even bother trying it for 30 days. Move that mountain one stone at a time. They also discuss the social media swindlers that are just trying to promote their own products or diet pills, and how to identify those that you shouldn't be listening to. Follow Dylan on his instagram at @dylanholveyfitness, and be sure to download his podcast, “The Holvey Hour” Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Dr. Sumanta (Monty) Pal and Dr. Kimmie Ng discuss the disturbing rise of early-onset gastrointestinal cancers, the unique challenges faced by younger patients, and key research that is shedding light on potential drivers of early diagnoses in colorectal cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello, everyone. I'm Dr. Monty Pal, and I'm a medical oncologist and professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. I'm really delighted to welcome you all to the ASCO Daily News Podcast as the show's new host. I'll be bringing you discussions with leaders in the oncology space on a variety of topics. I've been working hard with the ASCO team on picking the ideal topics to bring to you, and I'm really delighted to introduce my first guest, a dear friend, Dr. Kimmie Ng, to discuss this huge problem that we're seeing nowadays of early-onset GI cancers. Dr. Ng is the associate chief of the Division of Gastrointestinal Oncology at the Dana-Farber Cancer Institute, and she's an associate professor of medicine at Harvard Medical School in Boston. She serves as co-director of the Colon and Rectal Cancer Program. She's also the founding director of the Young-Onset Colorectal Cancer Center at Dana-Farber. I'm sure we'll talk a little bit about that today.  Just to note, our full disclosures are available in the transcript of this episode.  Dr Ng, it's so great to have you on the podcast. Thanks so much for joining us. Dr. Kimmie Ng: Thank you so much for having me. It's great to be here. Dr. Sumanta (Monty) Pal: I'm going to refer to you as Kimmie, if you don't mind, for the rest of the podcast here. Please, we'll go by first names, if you don't mind.  Your research has really done so much to help improve our understanding of early-onset GI cancers. You've done a lot of work to increase awareness in this space. I don't think there's a couple of months that passes by when I don't see you on television on Good Morning America or other shows really broadcasting this really critical message. I think there's a certain sensitivity that we all have to this issue, right? I mean, because receiving a cancer diagnosis at any age is very challenging, but I'm sure that young patients who face a colorectal cancer diagnosis have some very unique challenges. Could you give us a sense of some of those? Dr. Kimmie Ng: I think the other reason why so many people are interested in this and feel touched by this is that it's not just gastrointestinal cancers that are increasing in young people, but actually a multitude of different cancers have been rising in young individuals. And while it is difficult at any age to receive a cancer diagnosis, we do all know that young people getting a diagnosis like this do face unique challenges. Studies have shown that over 80% have children under the age of 18 when they are diagnosed with colorectal cancer, for example, under the age of 50. And many experience career and education disruptions. They are in what we call the ‘sandwich generation,' where they're not only taking care of young families or starting to think about starting a young family, but they're also taking care of elderly parents. So it's just a very busy stage of life, and to then be facing a usually terminal cancer diagnosis, it is extremely challenging. The other factors that we've seen that seem to be unique or more prevalent in young patients is that there are higher levels of psychosocial distress, depression, and anxiety, and a majority of patients do need medical attention and treatment for those things, whether it's medication treatment or whether it's counseling or support from psychosocial oncologists. And so the other big issue is fertility. We know that so many of the treatments that these young patients receive do permanently and negatively impact fertility. And for a person who is young, who may still be trying to expand their family or again start a family, it is very important that these young patients do receive counseling about fertility preservation prior to starting treatment. Dr. Sumanta (Monty) Pal: You know, it's so interesting you bring this up, and I think about a patient who's in their 40s diagnosed with this disease. They're in the same demographic as I am, as you are. You know, I'm 44 years old, and you know, I'm thinking about my 11- and 12-year-old and my aging parents, right? I mean, the dilemmas that you highlighted are precisely what I'm facing in life, and it's so true, right? If I had to take my day-to-day and superimpose on that a colorectal cancer diagnosis, it would just be problematic in so many spheres, so many spheres. Dr. Kimmie Ng: Absolutely. And because we did think going into this, starting our Young-Onset Colorectal Cancer Center, that these patients will need unique supports, we did conduct a qualitative study and held some focus groups of young-onset colorectal cancer patients as well as their caregivers. And we really identified four primary themes that I think reflect a lot of the experience of patients with cancer, no matter what type of cancer when they're diagnosed young. And the first is the need, feeling overwhelmed by the healthcare system, and the need for patient navigation. As we know, a lot of these patients are previously healthy before they're facing this very serious diagnosis. The second is the need for peer-to-peer support, where they really value connecting with other young patients going through a similar experience. The third, we talked about already, the need for kind of formal psychosocial support in the form of psychosocial oncologists or psychiatrists or social workers. And the last is an interest in research. They are really very invested in getting germline genetic testing as well as somatic genomic profiling to help guide their therapy. Dr. Sumanta (Monty) Pal: That's really encouraging to hear that they themselves are interested in participating in research. I mean, obviously, that's a great way to move the field forward. I view your area of work here as being such a vexing problem because no matter what way you slice it, young-onset colorectal cancer still remains a relatively small proportion of all diagnoses. So how do you go about studying this phenomenon? I mean, it must be challenging to really sort of investigate underlying causes when ostensibly this is still a small piece of the pie. Dr. Kimmie Ng: That is such a great question and is one of the challenges me and my research team think about every single day. As you mentioned, one of the major barriers is that although these cancers are rising in young people, the absolute number of patients being diagnosed is still relatively small, and if it's going to take large scale epidemiologic studies to really understand, for example, what the dietary and lifestyle risk factors are, you need a considerable number of patients in order to have enough power to reach definitive conclusions.  And so this is where it is so important to collaborate. Any single institution is not going to see enough young-onset patients with colorectal cancer to be able to do this work on their own. And so I have really been intent on establishing an international prospective cohort study of patients with young-onset colorectal cancer so that we can increase the numbers of patients we partner with to try to answer these questions, but also so that we can study this on a global scale, because unfortunately this is not something that's just plaguing the United States. It is actually happening in multiple countries around the world. So that is one barrier.  The second, I would say, is that we think it's early life exposures to whatever environmental factor it is that's causing the rise that is likely contributing the most. And so if you imagine how difficult it would be to start studying individuals from when they're children through adolescence, through adulthood, and then all the way until a cancer diagnosis is obtained, a study like that would take too long, would cost too much, and really wouldn't be feasible. So we need to think of alternative ways to really try and answer this question of what is driving this rise in young-onset colorectal cancer. Dr. Sumanta (Monty) Pal: Honestly, Kimmie, this seems like almost an unfair question in the context of what you just mentioned, the challenges in terms of ascertaining causality, right? I'll tell you, I cheated a little bit ahead of this podcast. Kimmie and I had dinner together in Los Angeles a couple months ago. She came out to deliver a Presidential Lectureship at City of Hope. We were delighted to have her. And we did have a couple of thoughts exchanged over potential drivers of these early diagnoses, leaning on perhaps one of the things that you and I are both interested in, the microbiome. But amongst all these things, vitamin D, microbiome, etc., and I won't hold you to this, do you have at least a general sense of what might be contributing to this early-onset phenomenon? Dr. Kimmie Ng: Yeah, as we talked about during my visit there to City of Hope, we do hypothesize that it is a complex interaction between our exposome, which is everything we are exposed to in our environment, which does include diet and lifestyle factors, interacting with host immunity and antitumor immunity, and as well as the microbiome and shaping the composition and diversity of the gut microbiome that are likely interacting to increase susceptibility to colorectal cancer at a younger age. And I will say one of the biggest discoveries, if you will, about what might be driving young-onset colorectal cancer was published a few months ago in Nature. And that paper identified a specific mutational signature caused by the genotoxin colibactin, which is often produced by an organism called pks+ E. coli, as being much more prevalent in younger patients with colorectal cancer than older patients. And so while it doesn't explain necessarily all of young-onset colorectal cancer and why it's rising, it does give us a clue that the microbiome is likely very important in perhaps why this is rising in young people. Dr. Sumanta (Monty) Pal: After you mentioned it, I went back and dove deep into that paper. I was fascinated, fascinated by the content there. And this is just a massive exploration across thousands of patients worldwide. So, I mean, if there is a way to get at least some hint of what's driving this phenomenon, I suppose that's it. So thank you for pointing me in the direction of that manuscript. Now that we've addressed the issue of diagnosis, if we could just, you know, verge on the topic of treatment, right? And this is something that I struggle with. When I have my young patients with kidney cancer, I don't know necessarily that my treatment paradigm changes a whole heck of a lot. I guess what I will say is I might be a little bit more aggressive about concepts like definitive management with surgery. I suppose perhaps their treatment tolerance is a little bit higher. But tell us about the setting of young-onset colorectal cancer. Is the philosophy any different in terms of the actual sort of management of these patients? Dr. Kimmie Ng: That's a great question, and actually I was honored to participate in the first international consensus guidelines group to try to come up with uniform recommendations for how to treat young patients with colorectal cancer. And you know, the overall consensus is just as you said, the medical care of these young patients right now is really not that much different than that of an older patient with colorectal cancer. There are a couple of distinctions. One is that all young patients should get germline genetic testing, given that there is a higher prevalence of pathogenic germline variants when you are diagnosed at a young age. And the second is what we've already talked about, which is that all young patients should be referred for counseling about fertility preservation prior to starting treatment. But otherwise, the chemotherapy regimens recommended, you know, surgery, radiation, all of that seems very similar to older patients. I will say that because most of our young patients with colorectal cancer are diagnosed with left-sided cancers, including rectal cancers, where some of the treatment may be morbid and result in lifelong complications, we do consider de-escalation of therapy and try to consider the long-term implications when it's safe to do so and won't compromise outcomes. The other concerning thing is that younger patients don't necessarily have a better prognosis than older patients. And multiple studies have shown this, that even though we both often treat younger patients more aggressively – they more often receive multi-agent chemotherapy, and more often undergo surgery and radiation – their survival is not necessarily correspondingly better than an older patient with colorectal cancer. So that suggests to us that maybe these cancers are indeed biologically different and perhaps more aggressive or perhaps less responsive to treatment. And so that is some of the focus of our research too, to understand what is actually different about these cancers and how they respond to treatment. Dr. Sumanta (Monty) Pal: It's such a paradox, isn't it, right? Because you just brought this to my mind. I guess on the one hand, our younger patients may be able to tolerate perhaps a greater amount of chemotherapy, targeted therapy, etc. But you're absolutely right. I mean, they do sort of have these lingering issues with side effects that may persist for much longer than the 80- or 90-year-old that we're treating in the clinic. I mean, these tend to be sort of lifelong consequences and sequelae that they're dealing with. So that really does evolve to be a challenge. You've kind of changed my mindset there a little bit. Dr. Kimmie Ng: Yeah, I do think survivorship issues and long-term complications of therapy do need to be considered, especially for a young person who we hope will live a very, very long time. And so part of the work that our Young-Onset Colorectal Cancer Center is doing, we are participating in a pilot navigation study where we navigate patients to survivorship earlier than we typically would, perhaps, for an older patient. And that's so we can get a head start on addressing some of those potential complications of therapy and hopefully mitigate them so that they don't become an issue long term. Dr. Sumanta (Monty) Pal: Do you think there's a role for de-escalation studies formally in these young populations of patients? Dr. Kimmie Ng: I think de-escalation studies are important overall, and specifically for locally advanced rectal cancer, which again is one of the most common types of colorectal cancer diagnosed in our young patients, there are certain populations that may be able to forgo the radiation treatment to the pelvis, for example, and there's more and more patients who now may become candidates for non-operative management where they may not necessarily need to have their rectal cancer surgically removed. And elimination potentially of both of those modalities of treatment can really avoid some of the most serious and morbid complications that often occur with these treatments. Dr. Sumanta (Monty) Pal: Really interesting. Now, this is not and will never be a political podcast, but you know, obviously we're dealing with the consequences of changes on funding and so forth that have evolved over time. And I think it's worth sort of speculating how the landscape of research may change on account of that. Could you comment perhaps a little bit on how some of the funding cuts that we've seen recently at the NIH might affect the body of work that you're so integrally involved in? Dr. Kimmie Ng: I am honestly very worried about the current funding environment. Colorectal cancer is the third most commonly diagnosed cancer among men and women in the United States and globally, and when you combine men and women together, the second leading cause of cancer death. But proportionally, we receive much less funding for colorectal cancer compared to other cancer types. And my thoughts have always been that perhaps this is because there is this stigma around colorectal cancer and maybe some of the symptoms associated with colorectal cancer. And so on top of that, to have additional challenges in obtaining funding, I worry what it will do to the pace of progress for especially young patients with this disease. Also, because of some new stipulations that perhaps international collaborations are being discouraged, I also worry about that aspect of it because young-onset colorectal cancer and gastrointestinal cancers in general is a global phenomenon happening in multiple countries around the world. And if we are to understand what the environmental factors are affecting the different rates of rise in these different countries, we do so much need that international collaboration. So yes, I am worried, and I do hope that conversations like this will spark an awareness of the need for more funding and continued funding into this disease. Dr. Sumanta (Monty) Pal: I will say that, and the audience can't see this because this is an audio program, but I'm wearing my Southwest Oncology shirt here, a SWOG, and it's one of the National Cancer Institute-funded cooperative groups. And you know, I was recently dismayed to find that, you know, funding got cut for international collaborations and enrollment in South America and Latin America. And this was traditionally actually a mainstay of our enrollment for many trials, including trials in rare cancers that present themselves in younger patients in the GU space. So, I completely agree with you. We've got to do something to address this funding issue to make sure that this body of work, both yours and mine, continues, without a doubt. Kimmie, this has been a delightful conversation. I really want to thank you for, you know, leading the charge in the young-onset colorectal cancer space, and you've done so much tremendous work here. Dr. Kimmie Ng: Thank you for having me. Dr. Sumanta (Monty) Pal: If you value the insights that you hear on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. And again, thank you for joining us today. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:   Dr. Sumanta (Monty) Pal @montypal Dr. Kimmie Ng @KimmieNgMD Follow ASCO on social media:    @ASCO on Twitter   ASCO on Bluesky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Sumanta (Monty) Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Kimmie Ng: Honoraria: Seagen, GlaxoSmithKline Consulting or Advisory Role: CytomX Therapeutics, Jazz Pharmaceuticals, Revolution Medicines, Abbvie, Bayer, Pfizer, Agenus, Johnson & Johnson/Janssen, Etiome, AstraZeneca Research Funding (Inst.): Pharmavite, Janssen Other Relationship: JAMA

Here at Talk About It, there are some conversations that are simply difficult to have, but are necessary. For so many of us, beginning a healthy lifestyle fits that description and is met with a lot of resistance. Luckily, Greg brought in your new Fitness Guru to get us motivated and talk about all things health - from sustainable fitness regiments to sustainable diet. We can do this! In this special two-part series, Greg talks to Dylan Holvey, a fitness trainer who not only has a personal practice with many clients, but also an active social media platform where he posts inspirational no-BS content that will help us get off the couch and begin the routines that will lead us to a healthy lifestyle. They discuss the practices that can help us develop good fitness habits, good nutritional habits, and the mindset required to not just give up after a few weeks. In this episode, we also have a guest appearance from friend-of-the-show Joey Hanley - a baseball coach and trainer who lives with epilepsy - to talk about how he thinks about diet and exercise when living with epilepsy. You don't want to miss this episode, your health and wellness is way too important! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Welcome to Part Two of You Asked, Janet Greenwood Answered! Greg sits down with epilepsy hero Janet Greenwood of Keck Medicine of USC in the final part of this two-episode feature. Janet is a Physician's Assistant for the epilepsy doctors at Keck, and she just so happens to be the primary clinician overseeing the care of Greg's son Jake for many years, so they have a wonderful history together. In this two-part episode, Greg asks Janet a series of FAQ's about epilepsy, from living with epilepsy, to being a caregiver, to treatment options. They cover a LOT of ground in these episodes, so be sure to get out a pen and take some notes! You won't want to miss what Janet has to say. Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

You asked, we answered! Well, actually Janet Greenwood answered! On this first episode of a special two-part feature, Greg sits down with epilepsy hero Janet Greenwood of Keck Medicine of USC. Janet is a Physician's Assistant for the epilepsy doctors at Keck, and she just so happens to be the primary clinician overseeing the care of Greg's son Jake for many years, so they have a wonderful history together. In this two-part episode, Greg asks Janet a series of FAQ's about epilepsy, from living with epilepsy, to being a caregiver, to treatment options. They cover a LOT of ground in these episodes, so be sure to get out a pen and take some notes! You won't want to miss what Janet has to say. Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

In this episode of Talk About It, actor/ comedian/ influencer and good friend of the show Stanzi Potenza returns to talk about something that can cause both celebration and disappointment alike... milestones. Everybody naturally loves to celebrate milestones. They can motivate us to keep pushing or show us that our progress is leading to positive outcomes, whether they are for an addiction that you have overcome, professional progress, even time between seizures. But are they designed by default to lead us to disappointment when we don't reach the next one? In the case of seizures, there is inevitability that a breakthrough seizure may - and will - occur, so is this really a healthy thing for patients or caregivers to do? Greg chats with Stanzi, because she recently posted that she had her first seizure in almost two years, which lead to some feelings of disappointment. The call she has to make to her mom, telling her followers about it, even coming out of a postictal state and realizing what has just happened. It can be discouraging when your pride and self-fulfillment is attached to not having seizures. So what is the right thing to do? Greg also has another friend of the show, Jonathan Shapiro, on to briefly give some hopeful perspective about reframing how we think about milestones. This is something we all deal with, so you do not want to miss this episode! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals.

Continuing our series on the Heroes of Epilepsy, Greg has his long-time friend Dr. Barry Gidal to talk about all things pharmaceutical on this episode! Dr. Gidal is a Professor of Pharmacy and past Chair of the Pharmacy Practice Division at the University of Wisconsin-Madison. Dr. Gidal talks about taking mystery and anxiety out of your experience with medicine and about talking with your pharmacist. They discuss the importance of checking your medications and journaling, differences between generic drugs, developments that Dr. Gidal is excited about, and so much more! This episode is not a tough pill to swallow, so don't miss it! Talk About It with Greg Grunberg is excited to be sponsored by Neurelis and by Jazz Pharmaceuticals 

On this episode of Talk About It, we break out the Gold Jacket to chat with Alan Faneca, retired NFL offensive lineman and NFL Hall of Fame Inductee! Alan and Greg have become friends through advocacy for epilepsy awareness over the years, because Alan was diagnosed with epilepsy when he was a teenager and played at the highest levels of football with the condition. He also has a daughter with a rare form of epilepsy, so this cause is really close to his heart. Ironically, Nick also has a connection to Alan through his time with the Pittsburgh Steelers and hosting events together, so this is really a friend reunion show! They discuss his diagnosis, how his family helps him deal with the condition, going through the process again with his daughter, and - of course - his induction into the NFL Hall of Fame in Canton, OH. This is an episode that you are seriously not going to want to miss! The Talk About It podcast is excited to be sponsored in part by Neurelis. The Talk About It podcast is excited to also be sponsored in part by Seizures Are Signs — dedicated to educating families on the importance of early and specific diagnosis by providing an assessment to help get the conversation started, educational information, stories from families who have found a diagnosis, links to advocacy groups, and more. For more information, go to SeizuresAreSigns.com. Seizures are Signs is made available by Jazz Pharmaceuticals.